Merck (MRK) Net Income towards Common Stockholders Growth (1y) (2010 - 2026)
Powered by 
Analysis
Merck (MRK) Net Income towards Common Stockholders Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | -0.05% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 284.27% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | -130.19% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | -19.23% |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | -108.13% |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 152.55% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | -91.06% |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 151.28% |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 44.59% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -130.19% |
| Mar 31, 2026 | -183.44% |
| Dec 31, 2025 | -20.89% |
| Sep 30, 2025 | 83.07% |
| Jun 30, 2025 | -18.92% |
| Mar 31, 2025 | 6.67% |
| Dec 31, 2024 | 405.38% |
| Sep 30, 2024 | -33.45% |
| Jun 30, 2024 | 191.44% |
| Mar 31, 2024 | 68.74% |
| Dec 31, 2023 | -140.62% |
| Sep 30, 2023 | 46.02% |
| Jun 30, 2023 | -251.23% |
| Mar 31, 2023 | -34.41% |
| Dec 31, 2022 | -19.78% |
| Sep 30, 2022 | -28.83% |
| Jun 30, 2022 | 155.43% |
| Mar 31, 2022 | 35.19% |
| Dec 31, 2021 | 279.91% |
| Sep 30, 2021 | 55.21% |